Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07201961 · ClinicalTrials.gov registry record
Nellcor™ Abbreviated Sensor Additional Data Collection
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 55
- Enrollment target
NCT07201961: Completed study, sponsored by Medtronic - MITG.
NCT07201961 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07201961 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
To collect data on a variety of market approved Nellcor™ pulse oximetry sensors with the Nellcor™ Pulse Oximetry device to support the market approval.
Primary Outcome
Performance will be determined by calculating the accuracy in terms of root mean square difference (ARMS) comparing the pulse rate measurement from the Nellcor Pulse Oximetry device to the heart rate measurements as obtained by ECG.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-07-24 |
| Est. Completion | 2025-08-26 |
What the finished NCT07201961 record still lists
NCT07201961 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07201961 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07201961 about?
NCT07201961 is a clinical study titled "Nellcor™ Abbreviated Sensor Additional Data Collection". To collect data on a variety of market approved Nellcor™ pulse oximetry sensors with the Nellcor™ Pulse Oximetry device to support the market approval.
What is the current status of trial NCT07201961?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2025-07-24. Estimated completion is 2025-08-26.
Who is sponsoring clinical trial NCT07201961?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI